Previous 10 | Next 10 |
Treatment with TATX-03a substantially reduced bronchitis and tracheitis severity in preclinical studies - New histopathology data show that the significantly reduced viral load observed after prophylactic and therapeutic treatment with TATX-03a is accompanied by minimal lung i...
IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the results from in vitro characterizations investigating TATX-21, a novel potential first-in-class antibody for Atherosclerosis Cardiovascular Disease (ACVD), will be presented in...
ImmunoPrecise Antibodies (IPA) says Dr.Yasmina Abdiche, chief scientific officer, or CSO, will resign effective July 1, to pursue other opportunities, and that the board has appointed Ilse Roodink to take over the role of chief scientific officer.Since 2019, Dr. Ilse Roodink has served as cha...
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that Dr. Yasmina Abdiche, Chief Scientific Officer, will resign effective July 1, 2021, to pursue other oppor...
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Dion Neame has joined the company’s Strategic Advisory Board (SAB). Dr. Neame joins at a sign...
- Demonstrating what the Company believes to be the first reported in vivo synergistic effects of a multi-antibody (3+) combination treatment - Dr. Ilse Roodink and Dr. Debby Kruijsen to host live webinar “Function First: Using complementary antibody platforms to fi...
Gainers: Reliance Global Group (RELI) +39%.InnSuites Hospitality Trust (IHT) +28%.Comstock Holding (CHCI) +19%.Moxian (MOXC) +17%.MultiPlan (MPLN) +16%.AMC Entertainment (AMC) +16%.ImmunoPrecise Antibodies (IPA) +16%.Verso (VRS) +15%.Farmer Bro (FARM) +14%.Flux Power (FLUX) +13...
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it has selected and retained LifeSci Advisors as investor relations agent of record. Jennifer Bath, ...
ImmunoPrecise Antibodies (IPA) announces that its subsidiary Talem Therapeutics has advanced development of a candidate panel of vetted, novel, therapeutic antibodies, collectively referred to as TATX-112, against an undisclosed target, into formal lead candidate characterization.Shares ...
Potential to Treat Parkinson’s and Other Neurodegenerative Diseases IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that its subsidiary Ta...
News, Short Squeeze, Breakout and More Instantly...
ImmunoPrecise Antibodies Ltd. Company Name:
IPA Stock Symbol:
NASDAQ Market:
VICTORIA, BC / ACCESSWIRE / April 22, 2024 / ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENS ai TM Platform. LENS ai , which is run by the company's subsidiary, BioStran...
VICTORIA, BC / ACCESSWIRE/ April 12, 2024 / InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability and speed challenges partnered with ImmunoPrecise Antibodies (NASDAQ:IPA) ("IPA"), an artificial intelligence-dri...
Immunoprecise Antibodies Ltd (NASDAQ:IPA), together with InterSystems, have collaborated to integrate the new vector search capability of the Int...